Director

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Institution	Shares	Value	Change
BlackRock	9,758,938	$365M	INCREASED
State Street	2,689,350	$101M	INCREASED
Pictet Asset Management Holding	2,075,375	$78M	INCREASED
Aberdeen Group	820,395	$31M	UNCHANGED
Fisher Asset Management	741,553	$28M	DECREASED

Insider	Type	Shares	Value	Date
Coelho Rogerio Vivaldi (Director)	SELL	3,000	$120K	2026-07-02
Stephanie Okey (Director)	AWARD	9,730	$349K	2026-06-18
Stephanie Okey (Director)	AWARD	5,925		2026-06-18
Wendell Wierenga (Director)	AWARD	9,730	$349K	2026-06-18
Wendell Wierenga (Director)	AWARD	5,925		2026-06-18

Crinetics Pharmaceuticals, Inc. (CRNX) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades